{
  "abstract": "Objectives The management of SLE varies worldwide. Current SLE treatment goals focus on controlling disease activity and preventing flares and organ damage accrual. LupusNet is the largest federated data network in SLE that combines and harmonizes data from 5 existing registries to enable greater data consistency and enhance understanding of global clinical presentations and outcomes of SLE. This study assessed treatment patterns for patients with SLE, categorized by disease severity, from LupusNet and a US claims database.Methods Data from 3 SLE registries in LupusNet, APLC (Asia Pacific), RELESSER (Europe), and Almenara (South America), were analyzed from 2012 to 2024 using a privacy-preserving federated data network approach where only aggregated results were shared. Additionally, data from the US Merative MarketScan® Commercial Claims and Encounters (CCAE) Database from 2019 to 2024 were included in the analysis. In LupusNet, data from patients with >/=3 years of follow-up and >/=3 follow-up visits were collected and stratified into mild, moderate, or severe disease based on a SLEDAI score at Year 3 follow-up visit ( table 1). In the US claims database, data from patients who were diagnosed with SLE were stratified by mild, moderate, or severe disease based on documented symptoms and clinical features (table 1). Treatment exposures (ie, glucocorticoids, antimalarials, immunosuppressants, biologic therapies, and other immunosuppressants/immunomodulators) were assessed over follow-up.Abstract PO:07:186 Table 1Classification of disease severity in patients with SLE from LupusNet and the Merative MarketScan® CCAE DatabaseAbstract PO:07:186 Figure 1Results LupusNet included 3857 eligible patients (3070, mild disease; 637, moderate; 150, severe). US claims data included 49,350 eligible patients (23,461, mild disease; 16,172, moderate; 9717, severe). Overall, 63%-65% of patients with mild disease, 76%-84% with moderate disease, and 89%-95% with severe disease received glucocorticoids in LupusNet and US claims data ( figure 1). Antimalarials were frequently prescribed in 58%-66% of patients, regardless of disease severity. Use of immunosuppressants varied with disease severity: 25%-50% of patients with mild disease, 43%-67% with moderate disease, and 69%-81% with severe disease received immunosuppressants. Biologics and other immunosuppressants/immunomodulators were utilized less frequently across all disease severity levels in LupusNet (4% and 2%-4%, respectively), while the use of these therapies increased with disease severity in US claims data (8%-44% and 4%-13%, respectively); biologic use was primarily off-label rituximab.",
  "authors": [
    {
      "affiliations": [
        "Grupo Oroño-Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina"
      ],
      "name": "Guillermo Pons-Estel"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Spring House, PA, USA"
      ],
      "name": "Ashley Orillion"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Horsham, PA, USA"
      ],
      "name": "Federico Zazzetti"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Horsham, PA, USA"
      ],
      "name": "Anna Sheahan"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Spring House, PA, USA"
      ],
      "name": "Clair Blacketer"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Beerse, Belgium"
      ],
      "name": "Michel Van Speybroeck"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Spring House, PA, USA"
      ],
      "name": "Sarah Gasman"
    },
    {
      "affiliations": [
        "Capgemini Consulting, Zurich, Switzerland"
      ],
      "name": "Reyhan Sonmez"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Spring House, PA, USA"
      ],
      "name": "Erika Noss"
    },
    {
      "affiliations": [
        "Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Cientifica del Sur, Lima, Perú",
        "Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú"
      ],
      "name": "Manuel F Ugarte-Gil"
    },
    {
      "affiliations": [
        "Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Cientifica del Sur, Lima, Perú",
        "Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú"
      ],
      "name": "Rocío V Gamboa-Cárdenas"
    },
    {
      "affiliations": [
        "Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Cientifica del Sur, Lima, Perú",
        "Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú"
      ],
      "name": "Víctor Pimentel-Quiroz"
    },
    {
      "affiliations": [
        "University of Nebraska Medical Center, Omaha, NE, USA"
      ],
      "name": "Kaleb Michaud"
    },
    {
      "affiliations": [
        "University of California San Francisco, San Francisco, CA, USA"
      ],
      "name": "Patricia Katz"
    },
    {
      "affiliations": [
        "Monash University, Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Clayton, Victoria, Australia"
      ],
      "name": "Rangi Kandane-Rathnayake"
    },
    {
      "affiliations": [
        "Monash University, Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Clayton, Victoria, Australia",
        "Monash Health Hospital, Rheumatology Department, Clayton, Victoria, Australia"
      ],
      "name": "Eric Morand"
    },
    {
      "affiliations": [
        "Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand"
      ],
      "name": "Worawit Louthrenoo"
    },
    {
      "affiliations": [
        "Monash University, Rheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Clayton, Victoria, Australia",
        "Monash Health Hospital, Rheumatology Department, Clayton, Victoria, Australia"
      ],
      "name": "Alberta Hoi"
    },
    {
      "affiliations": [
        "Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan"
      ],
      "name": "Yi-Hsing Chen"
    },
    {
      "affiliations": [
        "National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore"
      ],
      "name": "Jiacai Cho"
    },
    {
      "affiliations": [
        "Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia"
      ],
      "name": "Laniyati Hamijoyo"
    },
    {
      "affiliations": [
        "Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan"
      ],
      "name": "Shue Fen Luo"
    },
    {
      "affiliations": [
        "University of Santo Tomas Hospital, Section of Rheumatology, Manila, Philippines"
      ],
      "name": "Sandra Navarra"
    },
    {
      "affiliations": [
        "University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia",
        "St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia"
      ],
      "name": "Mandana Nikpour"
    },
    {
      "affiliations": [
        "Department of Rheumatology, University Hospital of Vigo, Vigo, Spain",
        "IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain"
      ],
      "name": "José María Pego-Reigosa"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain"
      ],
      "name": "Iñigo Rúa-Figueroa"
    },
    {
      "affiliations": [
        "Research Unit of the Spanish Society of Rheumatology, Madrid, Spain"
      ],
      "name": "Zulema Plaza"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain"
      ],
      "name": "María Galindo-Izquierdo"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain"
      ],
      "name": "Julia Martínez-Barrio"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain"
      ],
      "name": "Jaime Calvo Alén"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Spain"
      ],
      "name": "Antonio Fernández-Nebro"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital Universitario de Jerez, Cádiz, Spain"
      ],
      "name": "Raúl Menor Almagro"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital De La Princesa, Madrid, Spain"
      ],
      "name": "Eva Tomero"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Hospital de Belvitge, Barcelona, Spain"
      ],
      "name": "Francisco Javier Narváez García"
    },
    {
      "affiliations": [
        "Johnson and Johnson, Spring House, PA, USA"
      ],
      "name": "Chetan S Karyekar"
    }
  ],
  "title": "PO:07:186 Customized therapy for SLE: how disease severity influences the use of corticosteroids and biologics in patients with SLE in the lupus federated data network (LupusNet) and a US claims database",
  "uid": "84ed2487-7a7f-553a-a14c-d7956f4a274d"
}